ClinicalTrials.Veeva

Menu

Effect of Red Ginseng Extract on Changes in Indicators of Immune Function in Vietnamese Healthy Volunteers

C

Centre of Clinical Pharmacology, Hanoi Medical University

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: Placebo hard capsule
Drug: KRG hard capsule

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05480774
BMRI-CT-2021-01

Details and patient eligibility

About

This is a placebo-controlled, randomized, double-blind, multiple dose study that evaluated the safety, tolerability, and changes in indicators of immune function of Korean Red Ginseng Extract in Vietnamese healthy subjects following oral administration of multiple dose of Korean Red Ginseng Extract as hard capsules or placebo to healthy adult men.

Enrollment

101 patients

Sex

All

Ages

20 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy adult male or female aged 20 to 65 years, inclusive at the time of informed consent
  • Have not any abnormalities of vital signs (temperature, systolic blood pressure (SBP) and diastolic blood pressure (DBP) and pulse rate), physical examinations, clinical laboratory tests (hematology, chemistry, and urinalysis).
  • Ability and willingness to provide written informed consent and to comply with the requirements of the protocol.
  • Peripheral white blood cells in the range of 3000 - 10,000/μL
  • Subjects with a history of being infected with COVID-19 within 12 months according to the diagnostic criteria of the Ministry of Health at the time of infection

Exclusion criteria

  • Pregnancy or lactation
  • For subjects of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception
  • Evidence of clinically significant acute or chronic hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psych, neurological, or neoplastic diseases (however, at the discretion of the principal investigator, subjects may also be considered)
  • Uncontrolled hypertension (SBP ≥160 mmHg and/or DBP ≥100 mmHg, measured following at least 10 mins of rest)
  • Uncontrolled diabetes (fasting glucose level above 126 mg/dL or diabetic patients who have initial treatment with antidiabetic drugs for ≤ 3 months)
  • Aspartate aminotransferase or alanine aminotransferase >=3.0 × upper limit of normal
  • Serum creatinine level > 2,4 mg/dL for male and > 1,8 mg/dL for female
  • Use of medications and dietary supplements that can affect immunity within 2 weeks before screening
  • Those who complain of severe gastrointestinal symptoms such as heartburn and indigestion
  • History of sensitivity or allergy to investigational product-related foods
  • Plan to participate in other research while participating in this research
  • Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study.
  • Failure of follow instructions for discontinuing immune-affecting dietary supplements during the wash-out period prior to trial participation

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

101 participants in 2 patient groups, including a placebo group

KRG hard capsules
Active Comparator group
Description:
Each KRG hard capsule contains 500 mg of red ginseng extract. Dosage of KRG hard capsule: oral administration of 1 capsule twice daily for 12 weeks.
Treatment:
Drug: KRG hard capsule
Placebo hard capsules
Placebo Comparator group
Description:
The composition of the Placebo hard capsule contains red ginseng flavor. Dosage of Placebo hard capsule: oral administration of 1 capsule twice daily for 12 weeks.
Treatment:
Drug: Placebo hard capsule

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems